RESUMO
BACKGROUND AND AIMS: Baseline cardiovascular toxicity risk stratification is critical in cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology Society (ICOS) score aims to assess this risk but lacks real-life validation. This study validates the HFA-ICOS score for anthracycline-induced cardiovascular toxicity. METHODS: Anthracycline-treated patients in the CARDIOTOX registry (NCT02039622) were stratified by the HFA-ICOS score. The primary endpoint was symptomatic or moderate to severe asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), with all-cause mortality and cardiovascular mortality as secondary endpoints. RESULTS: The analysis included 1066 patients (mean age 54 ± 14 years; 81.9% women; 24.5% ≥65 years). According to the HFA-ICOS criteria, 571 patients (53.6%) were classified as low risk, 333 (31.2%) as moderate risk, 152 (14.3%) as high risk, and 10 (0.9%) as very high risk. Median follow-up was 54.8 months (interquartile range 24.6-81.8). A total of 197 patients (18.4%) died, and 718 (67.3%) developed CTRCD (symptomatic: n = 45; moderate to severe asymptomatic: n = 24; and mild asymptomatic: n = 649). Incidence rates of symptomatic or moderate to severe symptomatic CTRCD and all-cause mortality significantly increased with HFA-ICOS score [hazard ratio 28.74, 95% confidence interval (CI) 9.33-88.5; P < .001, and hazard ratio 7.43, 95% CI 3.21-17.2; P < .001) for very high-risk patients. The predictive model demonstrated good calibration (Brier score 0.04, 95% CI 0.03-0.05) and discrimination (area under the curve 0.78, 95% CI 0.70-0.82; Uno's C-statistic 0.78, 95% CI 0.71-0.84) for predicting symptomatic or severe/moderate asymptomatic CTRCD at 12 months. CONCLUSIONS: The HFA-ICOS score effectively categorizes patients by cardiovascular toxicity risk and demonstrates strong predictive ability for high-risk anthracycline-related cardiovascular toxicity and all-cause mortality.
RESUMO
OBJECTIVE: The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT). RESEARCH DESIGN AND METHODS: COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. RESULTS: There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44-0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008). CONCLUSIONS: Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention.
Assuntos
Sistema Cardiovascular , Doença da Artéria Coronariana , Diabetes Mellitus Tipo 2 , Infarto do Miocárdio , Humanos , Colchicina/uso terapêutico , Colchicina/efeitos adversos , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/induzido quimicamente , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/prevenção & controle , Doença da Artéria Coronariana/tratamento farmacológicoRESUMO
Background and objective:Thromboembolic risk is higher in women than men with non-valvular atrial fibrillation (NVAF). Published data indicate variability in antithrombotic use by gender and region. We analyzed gender-specific antithrombotic treatment patterns in Spain and rest of Western Europe (rWE) in patients with NVAF.Methods:GLORIA-AF (Phase III) is a global, prospective, observational study which enrolled newly diagnosed NVAF patients with CHA2DS2-VAScs≥1 (20142016). Analyses were performed comparing antithrombotic treatments by gender in Spain and rWE.Results:This analysis included 1163 and 7972 patients from Spain and rWE, respectively. Stroke risk was higher in women than men in both Spain and rWE. While in rWE, bleeding risk and antithrombotic treatment pattern were similar between genders, in Spain bleeding risk in women was lower and more females compared to men received OACs (95.0% versus 92.4%, d=−0.1078, respectively). Fewer Spanish patients received direct oral anticoagulants (DOACs) (women 32.1%, men 25.3%) than vitamin-K-antagonists (VKAs) (women 63.0%, men 67.1%) vs. rWE patients. In Spain women received more DOACs compared to men (56.0% versus 44.0%).Conclusions:OAC rates were higher in Spain as compared to rWE. More women received OACs in Spain, while in rWE no difference by gender was observed. DOACs in rWE are the most prescribed OAC while in Spain, due to prescription barriers, its use remains low for both genders and VKAs are preferred. Spanish women received more DOACs compared to men. (NCT01468701). (AU)
Antecedentes y objetivo:El riesgo tromboembólico es mayor en mujeres que en varones con fibrilación auricular no valvular (FANV). Existen diferencias en el uso de anticoagulantes (ACO) según sexo y zona geográfica. Se estudiaron los patrones de anticoagulación por sexo en España y el resto de Europa Occidental (rEO) en pacientes con FANV.Métodos:GLORIA-AF es un estudio observacional prospectivo (fase III) que incluyó a pacientes con diagnóstico reciente de FANV y CHA2DS2-VASc>1 (2014-2016). Se analizó la prescripción de anticoagulantes por sexo en España y el rEO.Resultados:Se incluyó a 1.163 pacientes de España y 7.972 del rEO. El riesgo de ictus fue superior en mujeres tanto en España como en el rEO. El riesgo de hemorragia y el tratamiento antitrombótico fueron similares en ambos sexos en el rEO; en España, el riesgo de hemorragia fue menor en mujeres y estas recibieron más ACO que los varones (95,0% vs. 92,4%, d=0,1078). En España, menos pacientes recibieron ACO directos (ACOD) (mujeres 32,1%, varones 25,3%) vs. antagonistas de la vitamina K (AVK) (mujeres 63,0%, varones 67,1%), y las mujeres recibieron más ACOD que los varones (56,0% vs. 44,0%).Conclusiones:En España se emplearon más ACO que en el rEO y más mujeres fueron tratadas con ACO, mientras que en el rEO no hubo diferencias por sexo. En el rEO, los ACOD se emplearon más. En España, los ACOD se emplean menos por restricciones de prescripción y se emplean más los AVK. Las mujeres españolas reciben más ACOD que los varones. (NCT01468701). (AU)
Assuntos
Humanos , Administração Oral , Anticoagulantes/efeitos adversos , Fibrilação Atrial/complicações , Fibrilação Atrial/tratamento farmacológico , Fibrinolíticos/efeitos adversos , Fatores Sexuais , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/prevenção & controle , Estudos Prospectivos , EspanhaRESUMO
Background: It is unknown whether an initial invasive strategy in patients with stable ischemic heart disease and at least moderate ischemia improves outcomes in patients with a history of heart failure (HF) or left ventricular dysfunction (LVD) when EF >35%, but <45%. Methods: Among 5179 participants randomized into the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), all of whom had LVEF >35%, we compared cardiovascular outcomes by treatment strategy in those with a history of HF or LV dysfunction (HF/LVD) at baseline versus those without HF/LVD. Median follow up was 3.2 years. Results: There were 398 (7.7%) participants with HF/LVD at baseline of whom 177 had HF/LVEF>45%, 28 had HF/LVEF 35-45% and 193 had LVEF 35-45% but no prior history of HF. HF/LVD was associated with more comorbidities at baseline, particularly prior myocardial infarction (MI), stroke and hypertension. Compared to those without HF/LVD, those with HF/LVD were more likely to experience a primary outcome composite of cardiovascular death, nonfatal MI, or hospitalization for unstable angina, HF, or resuscitated cardiac arrest; four-year cumulative incidence rate (22.7% vs. 13.8%), cardiovascular death or MI (19.7% vs. 12.3%), and all-cause death or HF (15.0% vs. 6.9%). Those with HF/LVD randomized to the invasive versus conservative strategy had a lower rate of the primary outcome (17.2% vs. 29.3%, difference in 4- year event rate -12.1%; 95% CI: -22.6, -1.6%), whereas those without HF/LVD did not (13.0% vs. 14.6%, difference in 4-year event rate -1.6%; 95% CI: -3.8%, 0.7%; p-interaction = 0.055). A similar differential effect was seen for the primary outcome, all-cause mortality, and CV mortality when invasive versus conservative strategy associated outcomes were analyzed with LVEF as a continuous variable for those with and without prior HF. Conclusions: ISCHEMIA trial participants with stable ischemic heart disease and at least moderate ischemia with a history of HF or LVD were at increased risk for the primary outcome. In the small, high-risk subgroup with HF and LVEF 35-45%, an initial invasive approach was associated with a better event-free survival. This result should be considered hypothesis generating.
Assuntos
Tratamento Conservador , Insuficiência Cardíaca , IsquemiaRESUMO
No disponible
Assuntos
Humanos , Hospitalização/estatística & dados numéricos , Tromboembolia/epidemiologia , Vasos Coronários/fisiopatologia , Infecções por Coronavirus/complicações , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/patogenicidade , Pacientes Internados/estatística & dados numéricos , Doenças Cardiovasculares/epidemiologia , Fatores de RiscoRESUMO
No disponible
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Coronavirus/complicações , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/patogenicidade , Síndrome do Desconforto Respiratório/complicações , Trombose Coronária/complicações , Síndrome do Desconforto Respiratório/diagnóstico , Infarto do Miocárdio com Supradesnível do Segmento ST/complicações , Fatores de RiscoRESUMO
INTRODUCCIÓN Y OBJETIVOS: Analizar la cinética de la enolasa neuroespecífica (EN) como biomarcador de pronóstico neurológico de los pacientes que sobreviven a una parada cardiaca tratados con control de temperatura. MÉTODOS: Análisis retrospectivo de pacientes ingresados tras sufrir una parada cardiaca dentro o fuera del hospital entre septiembre de 2006 y mayo de 2018 en un centro terciario y enfriados a 32-34°C durante 24 h. Las muestras de EN se tomaron al ingreso hospitalario y a las 24, 48 y 72 h del retorno a circulación espontánea (RCE). El estado neurológico se evaluó a los 3 meses mediante la escala Cerebral Performance Category (CPC) y se categorizó como favorable (CPC 1-2) o desfavorable (CPC 3-5). RESULTADOS: De los 451 pacientes, 320 cumplían los criterios de inclusión (el 80,3% varones; media de edad, 61+/-14,1 años). De estos, 174 (54,4%) sobrevivieron con una evolución neurológica favorable. Los pacientes con estado neurológico desfavorable tenían valores de EN más altos al ingreso hospitalario y a las 24, 48 y 72 h del RCE. A las 48 y las 72 h, los valores de EN predijeron un estado neurológico desfavorable, con áreas bajo la curva de 0,85 (IC95%, 0,81-0,90) y 0,88 (IC95%, 0,83-0,93). Además, el área bajo la curva de los valores delta de EN entre las 72 h y el ingreso hospitalario fue de 0,90 (IC95%, 0,85-0,95), y en el análisis multivariante resultó predictor independiente (p <0,001). CONCLUSIONES: En pacientes que sobrevivieron a una parada cardiaca tratados con control de la temperatura, se ha demostrado que los valores delta de EN entre las 72 h del RCE y el ingreso hospitalario son un potente predictor de resultado neurológico desfavorable
INTRODUCTION AND OBJECTIVES: To analyze neuron-specific enolase (NSE) kinetics as a prognostic biomarker of neurological outcome in cardiac arrest survivors treated with targeted temperature management. METHODS: We performed a retrospective analysis of patients resuscitated from in- or out-of-hospital cardiac arrest admitted from September 2006 to May 2018 in a single tertiary care center and cooled to 32°C to 34°C for 24 hours. Blood samples for measurement of NSE values were drawn at hospital admission and at 24, 48, and 72hours after return of spontaneous circulation (ROSC). Neurological outcome was evaluated by means of the Cerebral Performance Category (CPC) score at 3 months and was characterized as good (CPC 1-2) or poor (CPC 3-5). RESULTS: Of 451 patients, 320 fulfilled the inclusion criteria and were analyzed (80.3% male, mean age 61+/-14.1 years). Among these, 174 patients (54.4%) survived with good neurological status. Poor outcome patients had higher median NSE values at hospital admission and at 24, 48 and 72 hours after ROSC. At 48 and 72 hours after ROSC, NSE predicted poor neurological outcome with areas under the receiver-operating characteristic curves of 0.85 (95%CI, 0.81-0.90) and 0.88 (95%CI, 0.83-0.93), respectively. In addition, delta NSE values between 72hours after ROSC and hospital admission predicted poor neurological outcome with an area under the receiver-operating characteristic curve of 0.90 (95%CI, 0.85-0.95) and was an independent predictor of unfavorable outcome on multivariate analysis (P <.001). CONCLUSIONS: In cardiac arrest survivors treated with targeted temperature management, delta NSE values between 72 hours after ROSC and hospital admission strongly predicted poor neurological outcome
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Parada Cardíaca Extra-Hospitalar/complicações , Doenças do Sistema Nervoso , Fosfopiruvato Hidratase/farmacocinética , Estudos Retrospectivos , Curva ROC , Centros de Atenção Terciária , Biomarcadores , Hipotermia Induzida , Fosfopiruvato Hidratase/sangue , Doenças do Sistema Nervoso/etiologiaRESUMO
No disponible
Assuntos
Humanos , Seio Coronário/cirurgia , Angina Pectoris/cirurgia , Isquemia Miocárdica/cirurgia , Isquemia Miocárdica/complicações , Stents/estatística & dados numéricosRESUMO
No disponible
Assuntos
Humanos , Cardiomiopatia Chagásica/diagnóstico , Peptídeo Natriurético Encefálico/análise , Biomarcadores/análise , Estudos Prospectivos , Sensibilidade e Especificidade , Eletrocardiografia , EcocardiografiaRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Cardiopatias Congênitas/complicações , Tumores Neuroendócrinos/epidemiologia , Complexo de Eisenmenger/complicações , Cianose , Paraganglioma/epidemiologia , Feocromocitoma/epidemiologiaRESUMO
No disponible
Assuntos
Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Infarto do Miocárdio/fisiopatologia , Anomalias dos Vasos Coronários/diagnóstico , Síndrome Coronariana Aguda/diagnóstico , Morte Súbita Cardíaca/etiologiaRESUMO
No disponible
Assuntos
Humanos , Fibrilação Atrial/tratamento farmacológico , Rivaroxabana/administração & dosagem , Antiarrítmicos/administração & dosagem , Resultado do TratamentoRESUMO
La hipercolesterolemia es uno de los más importantes factores de riesgo de enfermedades cardiovasculares, y no siempre es posible controlarla con los tratamientos convencionales: dieta, ejercicio y fármacos hipolipemiantes. La inhibición de la proteína PCSK9 mediante anticuerpos monoclonales aumenta el número de receptores de colesterol unido a lipoproteínas de baja densidad (cLDL) en el hepatocito y, por lo tanto, contribuye a su destrucción. Con estos fármacos, empleados solos o añadidos a estatinas o ezetimiba, se ha observado una reducción del colesterol muy importante que permite mantener las cifras de cLDL de la mayoría de los pacientes en lo recomendado por las guías de práctica clínica. Para averiguar su eficacia clínica, se han diseñados 3 estudios multicéntricos de morbimortalidad con alirocumab, evolocumab y bococizumab. En el estudio del evolocumab, un anticuerpo monoclonal 100% humano, se demostró una reducción significativa del objetivo primario de eficacia, que incluía mortalidad cardiovascular, infarto agudo de miocardio, ictus, angina inestable o revascularización miocárdica. Por el contrario, en el estudio con bococizumab, un anticuerpo humanizado, no 100% humano, no se observó beneficio clínico, lo que se atribuye a una disminución de la eficacia secundaria a la creación de anticuerpos contra el fármaco. Esta nueva opción terapéutica ya está disponible en la práctica clínica y supone un nuevo avance en la prevención de las enfermedades cardiovasculares (AU)
Hypercholesterolaemia is one of the major cardiovascular risk factors; however, conventional treatment with diet, exercise and cholesterol-lowering drugs are insufficient to control low-density lipoprotein (LDL) cholesterol in a significant number of patients. Inhibition of the PCSK9 protein by using specific monoclonal antibodies increases the number of LDL cholesterol receptors in the hepatocyte, contributing to LDL destruction. The use of these drugs, whether as monotherapy or in combination with statins and ezetimibe, significantly reduces LDL cholesterol, allowing LDL cholesterol levels in most patients to be maintained within limits recommended by clinical practice guidelines. To determine their clinical efficacy, 3 multicenter trials of morbidity and mortality have been conducted with alirocumab, evolocumab and bococizumab. The trial involving evolocumab, a fully human monoclonal antibody, demonstrated a significant reduction of the primary efficacy endpoint, including cardiovascular mortality, myocardial infarction, stroke, unstable angina or myocardial revascularisation. However, no clinical benefit was observed with bococizumab (a humanised but not fully human monoclonal antibody), probably due to a decrease in efficacy secondary to the formation of anti-drug antibodies. This new therapeutic option is already used in clinical practice and is considered a new advance in the prevention of cardiovascular disease (AU)
Assuntos
Humanos , Hipercolesterolemia/diagnóstico , Doenças Cardiovasculares/diagnóstico , LDL-Colesterol , Anticorpos Monoclonais/uso terapêutico , Pró-Proteína Convertase 9/metabolismo , Anticolesterolemiantes/uso terapêutico , Fatores de Risco , Indicadores de Morbimortalidade , Doenças Cardiovasculares/prevenção & controle , Revascularização Miocárdica/métodosRESUMO
El tratamiento hipolipemiante es uno de los pilares de la prevención cardiovascular; en la prevención secundaria de pacientes con cardiopatía isquémica, es una de las estrategias de mayor eficacia, pero el tratamiento hipolipemiante actual, junto con cambios en el estilo de vida, en una importante proporción de pacientes no consigue alcanzar los objetivos recomendados por las guías de práctica clínica. Los inhibidores PCSK9 han mostrado eficacia y seguridad en el tratamiento de la dislipemia y se han incorporado recientemente en España para empleo clínico con el objetivo de reducir el riesgo cardiovascular debido a su efecto en la reducción del colesterol unido a lipoproteínas de baja densidad (AU)
Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups (AU)
Assuntos
Humanos , Hipolipemiantes/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Doença das Coronárias/complicações , Anticorpos Monoclonais/uso terapêutico , Avaliação das Necessidades , Hiperlipidemias/epidemiologia , Padrões de Prática Médica , SubtilisinaRESUMO
Introducción y objetivos: Los inhibidores de la tirosina cinasa (ITC) denominados de segunda generación (dasatinib y nilotinib) empleados en el tratamiento de la leucemia mieloide crónica (LMC) han demostrado un beneficio frente a imatinib en respuestas alcanzadas y progresiones de la enfermedad. No obstante, estos inhibidores se han relacionado con alguna forma de toxicidad cardiovascular, ocurriendo en su mayor parte en pacientes con factores de riesgo cardiovasculares (FRCV). El control de los FRCV se debe considerar por tanto imprescindible para un tratamiento adecuado de la LMC. En la actualidad, debido a la falta de recomendaciones en pacientes con LMC, el tratamiento de los FRCV se realiza de forma muy heterogénea. El objetivo de este trabajo es elaborar recomendaciones sobre la prevención y el seguimiento de episodios cardiovasculares (ECV) en pacientes con LMC tratados con ITC. Material y métodos: Expertos del Grupo Español de Leucemia Mieloide Crónica, junto con expertos en riesgo cardiovascular, hemos elaborado, con base en una reunión de consenso, recomendaciones de prevención y seguimiento de ECV en pacientes con LMC tratados con ITC. Resultados: En este documento se muestran las recomendaciones de consenso con respecto a la información necesaria a recoger en la historia clínica, la toma de decisiones terapéuticas, así como el tratamiento y el seguimiento de los FRCV. Conclusiones: El tratamiento con ITC requiere un manejo integral del paciente que deberá realizarse desde un abordaje multidisciplinar, en el que tanto la prevención como el tratamiento de los FRCV es fundamental (AU)
Introduction and objectives: The second generation tyrosine kinase inhibitors (TKI, dasatinib and nilotinib) used in chronic myeloid leukemia (CML) treatment have shown a benefit compared to imatinib in responses achieved and disease progression. However, both have been related to some cardiovascular toxicity, being more frequent in patients with cardiovascular risk factors (CVRFs). Nowadays, due to the lack of recommendations for CML patients, CVRF management is carried out heterogeneously. The aim of this work is to develop recommendations on the prevention and monitoring of cardiovascular events (CVD) in patients with CML treated with TKIs. Material and methods:Experts from the Spanish Group of Chronic Myeloid Leukemia together with experts in cardiovascular risk have elaborated, after a consensus meeting, recommendations for the prevention and follow-up of CVE in patients with CML treated with TKI. Results: Recommendations regarding the necessary information to be collected on clinical history, treatment decisions, as well as treatment and monitoring of CVRFs are shown in this document. Conclusions: TKI treatment requires comprehensive patient management from a multidisciplinary approach, in which both the prevention and management of CVRFs are essential (AU)
Assuntos
Humanos , Masculino , Feminino , Leucemia Mielogênica Crônica BCR-ABL Positiva/complicações , Leucemia Mielogênica Crônica BCR-ABL Positiva/epidemiologia , Mesilato de Imatinib/uso terapêutico , Fatores de Risco , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/epidemiologia , Conferências de Consenso como Assunto , Assistência Integral à Saúde/métodos , Assistência Integral à Saúde/tendências , Assistência Integral à Saúde/organização & administração , Assistência Integral à Saúde/normas , Leucemia Mielogênica Crônica BCR-ABL Positiva/prevenção & controle , Leucemia Mielogênica Crônica BCR-ABL Positiva/fisiopatologiaRESUMO
No disponible